Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole effect on zongertinib pharmacokinetics in healthy males
NCT05833139Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zongertinib, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity at 287 hours and Maximum Measured Concentration of Zongertinib in Plasma at 287 hours. Started Apr 2023; status: completed.
02
Drugs
zongertinib
Beyond the preview
Go deeper on NCT05833139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833139.